MIV 711

Drug Profile

MIV 711

Alternative Names: MIV-711

Latest Information Update: 10 Jun 2017

Price : $50

At a glance

  • Originator Medivir AB
  • Class Antineoplastics; Osteoporosis therapies; Small molecules
  • Mechanism of Action Cathepsin K inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Osteoarthritis
  • Discontinued Bone metastases; Osteoporosis

Most Recent Events

  • 09 Jun 2017 An independent Data Monitoring Committee recommends continuation of the phase IIa extension trial in Osteoarthritis after evaluation of accumulated safety data from the parent study and data to date from the extension trial
  • 09 Jun 2017 Medivir completes enrolment in a phase II extension trial in Osteoarthritis in Bulgaria, Germany, Georgia and Moldova
  • 01 Feb 2017 An independent Data Monitoring Committee recommends continuation of the MIV-711-201 phase IIa study in Osteoarthritis after evaluation of safety data from 200 patients
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top